[HTML][HTML] HDAC inhibitors in acute myeloid leukemia
E San José-Enériz, N Gimenez-Camino, X Agirre… - Cancers, 2019 - mdpi.com
Acute myeloid leukemia (AML) is a hematological malignancy characterized by uncontrolled
proliferation, differentiation arrest, and accumulation of immature myeloid progenitors …
proliferation, differentiation arrest, and accumulation of immature myeloid progenitors …
[HTML][HTML] Epigenetic therapy of cancer with histone deacetylase inhibitors
KC Lakshmaiah, LA Jacob, S Aparna… - Journal of cancer …, 2014 - journals.lww.com
Epigenetics is the study of heritable alterations in gene expression that are not accompanied
by the corresponding change in DNA sequence. Three interlinked epigenetic processes …
by the corresponding change in DNA sequence. Three interlinked epigenetic processes …
Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy
K Keller, M Jung - Epigenetic Therapy of Cancer: Preclinical Models and …, 2013 - Springer
Histone deacetylases are key enzymes of epigenetic regulation and are therefore involved
in crucial cellular events like transcription, differentiation, apoptosis and cell division. The …
in crucial cellular events like transcription, differentiation, apoptosis and cell division. The …
Molecular therapy for acute myeloid leukaemia
CC Coombs, MS Tallman, RL Levine - Nature reviews Clinical oncology, 2016 - nature.com
Acute myeloid leukaemia (AML) is a heterogeneous disease that is, in general, associated
with a very poor prognosis. Multiple cytogenetic and molecular abnormalities that …
with a very poor prognosis. Multiple cytogenetic and molecular abnormalities that …
[HTML][HTML] Histone acetyltransferases and histone deacetylases in B-and T-cell development, physiology and malignancy
L Haery, RC Thompson, TD Gilmore - Genes & cancer, 2015 - ncbi.nlm.nih.gov
The development of B and T cells from hematopoietic precursors and the regulation of the
functions of these immune cells are complex processes that involve highly regulated …
functions of these immune cells are complex processes that involve highly regulated …
Novel drugs for older patients with acute myeloid leukemia
G Montalban-Bravo, G Garcia-Manero - Leukemia, 2015 - nature.com
Acute myeloid leukemia (AML) is the second most common form of leukemia and the most
frequent cause of leukemia-related deaths in the United States. The incidence of AML …
frequent cause of leukemia-related deaths in the United States. The incidence of AML …
[HTML][HTML] The synergistic anti-tumor activity of EZH2 inhibitor SHR2554 and HDAC inhibitor chidamide through ORC1 reduction of DNA replication process in diffuse …
X Wang, D Wang, N Ding, L Mi, H Yu, M Wu, F Feng… - Cancers, 2021 - mdpi.com
Simple Summary The EZH2-targeted drugs have demonstrated notable therapeutic effects
in EZH2 mutant B-cell lymphoma patients. In this study, we demonstrated that the …
in EZH2 mutant B-cell lymphoma patients. In this study, we demonstrated that the …
[HTML][HTML] Histone deacetylase inhibition in the treatment of acute myeloid leukemia: the effects of valproic acid on leukemic cells, and the clinical and experimental …
H Fredly, BT Gjertsen, Ø Bruserud - Clinical epigenetics, 2013 - Springer
Several new therapeutic strategies are now considered for acute myeloid leukemia (AML)
patients unfit for intensive chemotherapy, including modulation of protein lysine acetylation …
patients unfit for intensive chemotherapy, including modulation of protein lysine acetylation …
Targeting acute myeloid leukemia with a proapoptotic peptide conjugated to a toll‐like receptor 2‐mediated cell‐penetrating peptide
Cell‐penetrating peptides provide a unique platform to create a new generation of cancer
therapeutics with enhanced efficacy and diminished toxicity. In our study, enhanced …
therapeutics with enhanced efficacy and diminished toxicity. In our study, enhanced …
[HTML][HTML] The histone deacetylase inhibitor SAHA acts in synergism with fenretinide and doxorubicin to control growth of rhabdoid tumor cells
K Kerl, D Ries, R Unland, C Borchert, N Moreno… - BMC cancer, 2013 - Springer
Background Rhabdoid tumors are highly aggressive malignancies affecting infants and very
young children. In many instances these tumors are resistant to conventional type …
young children. In many instances these tumors are resistant to conventional type …